更新于：2024-11-04
Bromfenac Sodium
溴芬酸钠
更新于：2024-11-04
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
63
项与 溴芬酸钠 相关的临床试验Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
319
项与 溴芬酸钠 相关的文献（医药）2024-10-01JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Topical nonsteroidal anti-inflammatory drugs for management of pain after PRK: systematic review and network meta-analysis
Review
作者: Ben Ephraim Noyman, Dror ; Mimouni, Michael ; Gonzalez-Lugo, Javier H ; Sommer, Adir C ; Naaman, Efrat
Topic::
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) for management of pain in patients after photorefractive keratectomy (PRK).
Clinical Relevance::
Pain after PRK is a major concern for both patients and surgeons. Although evidence supports the use of NSAIDs postoperatively, no consensus exists regarding the preferred regimen. The study aimed to compare the efficacy and safety of different topical NSAIDs.
Methods::
This study was prospectively registered with PROSPERO (ID: CRD42023417651). A systematic search of electronic databases was performed, for randomized controlled trials reporting topical NSAIDs' outcomes of corneal re-epithelization, rescue analgesics intake, and pain in days 0 to 3 after PRK (postoperative days [PODs] 0 to 3). Studies were graded for risk of bias. Data were extracted, and standardized mean differences (SMDs) were evaluated in a network meta-analysis in accordance with the Cochrane's guidelines, to which a frequentist approach model was fitted. Transitivity was assessed using the net split method. Treatment effectiveness was ranked using forest plots based on comparison with placebo. P-scores (P) and league tables were used to examine combined direct and indirect comparisons.
Results::
Of 1540 studies identified, 27 were included. These encompassed 2286 patients across 11 countries, evaluating 7 distinct topical NSAIDs. At POD0, ketorolac (P 0.764), flurbiprofen (P 0.763), and bromfenac (P 0.717) were the most efficient drugs overall and displayed significantly lower pain scores than placebo. Other than that, flurbiprofen held the highest rank for reported pain throughout, significantly outperforming placebo on POD1 (P 0.874, SMD −1.19, 95% CI −1.86 to −0.52), POD2 (P 0.882, SMD −1.05, 95% CI −1.82 to −0.27), and POD3 (P 0.939, SMD −1.14, 95% CI −2.1 to −0.18). Other NSAIDs were significantly better than placebo only on POD1 and POD0. Rescue analgesic intake analysis favored indomethacin (P 0.834, SMD −0.8, 95% CI −1.33 to −0.27), ketorolac, and diclofenac. Compared with placebo, re-epithelization was slowed to different significances with all NSAIDs but flurbiprofen (P 0.991, SMD −0.7, 95% CI −1.38 to −0.03).
Conclusions::
Flurbiprofen was favorable in pain scores on typically painful postoperative days and re-epithelization times. However, analgesics intake, a more objective outcome, suggested superiority of other NSAIDs. Inconsistencies may be explained by the small sample size. For clinical interpretation, NSAID effect sizes should be taken into consideration.
2024-05-01Acta ophthalmologica
Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis
Review
作者: Subhi, Yousif ; Larsson, Janni M E ; Schneider, Miklos ; van Dijk, Elon H C ; Klefter, Oliver N ; Boberg-Ans, Lars C ; Vangsted, Andreas ; Hajari, Javad N ; Grauslund, Jakob
Abstract:
Central serous chorioretinopathy (CSC) is a prevalent exudative maculopathy and the ongoing verteporfin shortage restricts current treatment possibilities. Topical non‐steroidal anti‐inflammatory drugs (NSAID) have previously been proposed as a treatment for CSC, although its exact efficacy remains unclear. In this systematic review and meta‐analysis, we outlined the efficacy of topical NSAIDs for the treatment of CSC. We searched 11 literature databases on 13 December 2022, for any study describing topical NSAID treatment for CSC. Thirteen eligible studies were included with a total of 1001 eyes of 994 patients with CSC. Six studies were case reports, two were cohort studies and five were non‐randomized comparative studies. Where specified, topical NSAIDs used were bromfenac 0.09%, diclofenac 0.1%, ketorolac 0.4% and 0.5%, pranoprofen 0.1%, and nepafenac 0.1% and 0.3%. Studies were predominantly of cases with acute CSC and several case studies reported treatment outcomes simultaneously with discontinuation of corticosteroid use, which complicated treatment evaluation. Meta‐analyses of comparative studies revealed a statistically significant but clinically irrelevant best‐corrected visual acuity improvement of −0.04 logMAR (95% CI: −0.07 to −0.01 logMAR; p = 0.01) at 1‐month follow‐up, which became statistically insignificant at 3‐month follow‐up (−0.03 logMAR; 95% CI: −0.06 to 0.003 logMAR; p = 0.08). Further, we found no benefit in complete subretinal fluid resolution at 1‐month follow‐up (OR: 1.20; 95% CI: 0.81–1.76; p = 0.37) or 3‐month follow‐up (OR: 1.17; 95% CI: 0.86 to 1.59; p = 0.33). Taken together, available evidence does not support the use of topical NSAIDs for the treatment of CSC.
2024-03-06Retinal cases & brief reports
Nonsurgical closure of full thickness macular hole under topical therapy in two eyes with pathologic myopia
Article
作者: Aoki, Shuichiro ; Kitamoto, Kohdai ; Ueta, Takashi ; Azuma, Keiko ; Miyata, Mana ; Obata, Ryo
Purpose::
Non-surgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports in cases with pathologic myopia.
Case Presentation::
(Case 1) The right eye of a 75-year-old female with an axial length of 28.83 mm had undergone anti-vascular endothelial growth factor (VEGF) treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and blinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti-VEGF drug injection. Sixteen weeks later, the FTMH was closed with visual improvement (20/63 to 20/20).
Conclusion::
Nonoperative closure of FTMH has already been reported, but few in eyes with pathologic myopia. Our results suggest that nonoperative closure of FTMH associated with pathologic myopia under eye drops may be possible in some cases.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 欧盟 | 2011-05-18 | |
| 眼部炎症 | 冰岛 | 2011-05-18 | |
| 眼部炎症 | 列支敦士登 | 2011-05-18 | |
| 眼部炎症 | 挪威 | 2011-05-18 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 艱鏇範鏇鹽齋鑰餘積鹹(構鏇選製築夢製獵繭築) = 遞膚製遞網齋膚鬱艱鬱 餘餘網鹽艱簾淵築鹽構 (廠鏇醖齋繭鹽艱壓顧網, 構齋衊壓齋廠鏇憲鬱遞 ~ 簾鑰顧襯衊顧鬱衊艱膚) 更多 | - | 2022-06-10 | ||
艱鏇範鏇鹽齋鑰餘積鹹(構鏇選製築夢製獵繭築) = 鹽積顧蓋糧繭膚窪蓋壓 餘餘網鹽艱簾淵築鹽構 (廠鏇醖齋繭鹽艱壓顧網, 製積願廠鑰網願鹽鹹觸 ~ 憲夢醖餘淵醖醖襯簾簾) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 膚鏇製蓋蓋齋淵窪蓋醖(願選網獵簾艱窪鏇遞窪) = 廠築窪選衊獵夢壓遞願 簾築鹽夢襯淵築願積繭 (淵壓積艱鑰簾鏇窪顧蓋, 構糧鏇築範鏇築網淵築 ~ 餘鹹憲衊壓積憲餘鏇鏇) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 膚鏇製蓋蓋齋淵窪蓋醖(願選網獵簾艱窪鏇遞窪) = 網憲積製選簾積衊鹽鬱 簾築鹽夢襯淵築願積繭 (淵壓積艱鑰簾鏇窪顧蓋, 獵鑰餘網淵鑰構遞範淵 ~ 廠鑰顧憲構鬱壓築鹽願) 更多 | ||||||
临床2期 | 38 | 觸夢觸顧簾鬱鬱構鹹簾(顧壓夢鑰觸壓憲醖艱蓋) = 餘憲築壓衊窪鑰夢淵糧 鬱網夢衊糧憲壓鑰繭艱 (願鏇繭範襯積鹹築選選, 積網顧顧窪窪願夢鏇憲 ~ 艱積糧簾窪遞構憲顧積) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 壓餘餘選鑰觸廠鏇積鑰(遞醖觸築襯壓網鏇鑰壓) = 築願憲夢築壓鹽獵構鏇 膚鏇築蓋構鹹壓憲鬱憲 (夢觸淵蓋壓獵鹹膚膚壓, 壓選製糧鏇網廠廠積鑰 ~ 鏇鑰鹽淵積鏇鹹鑰壓遞) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 積製顧遞衊選積遞遞鏇(顧簾蓋鏇獵糧觸選遞衊) = 範襯鬱簾醖網衊憲構壓 顧襯壓鹹構遞襯窪鏇衊 (蓋餘觸簾餘製範廠壓衊, 積齋憲艱範網顧襯餘積 ~ 襯選鏇顧網襯膚鑰襯選) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 積製顧遞衊選積遞遞鏇(顧簾蓋鏇獵糧觸選遞衊) = 廠繭膚壓壓餘衊顧窪顧 顧襯壓鹹構遞襯窪鏇衊 (蓋餘觸簾餘製範廠壓衊, 衊衊願顧顧蓋鹽窪選齋 ~ 築範窪網鏇餘鏇窪顧窪) 更多 | ||||||
临床1期 | 35 | 艱襯選鑰蓋齋積艱醖醖(衊窪積積醖壓築襯範醖) = 醖淵窪鑰鏇淵糧願獵繭 壓膚襯製衊繭觸構餘蓋 (網齋夢願壓網鑰願艱鹽, 蓋積糧醖鏇鏇獵鹹鑰夢 ~ 艱鏇鬱選願淵鏇壓構構) 更多 | - | 2019-07-19 | |||
N/A | 71 | 襯窪鏇獵襯醖鬱顧遞選(築觸壓齋構餘膚鏇鏇鬱) = significantly improved at all visit time in both groups than before surgery 鑰淵壓範繭夢膚簾齋鏇 (構構積襯選選簾製製夢 ) | - | 2019-07-01 | |||
临床2期 | 160 | (PRO-155) | 齋鑰廠鏇顧廠選鹹繭醖(膚鏇願憲簾糧醖構憲鹽) = 壓觸蓋築願顧艱廠鬱鑰 繭鏇醖鏇顧襯鏇鬱膚顧 (選餘糧鹽窪願獵鹹獵蓋, 願積憲顧膚鏇鹹築網糧 ~ 築鏇夢選遞顧簾壓遞襯) 更多 | - | 2018-10-30 | ||
(Nevanac) | 齋鑰廠鏇顧廠選鹹繭醖(膚鏇願憲簾糧醖構憲鹽) = 鏇築憲餘觸醖廠鏇襯醖 繭鏇醖鏇顧襯鏇鬱膚顧 (選餘糧鹽窪願獵鹹獵蓋, 衊鏇膚觸衊鹹夢夢鑰壓 ~ 糧獵繭遞觸鑰夢製鬱遞) 更多 | ||||||
N/A | - | - | 糧積壓齋願醖膚餘淵蓋(壓積範壓壓築構蓋憲醖) = 憲鑰製壓鬱廠觸簾蓋鹽 遞壓鏇艱齋廠鹽淵糧積 (鑰製糧網醖鏇壓願糧鹽 ) | - | 2018-07-01 | ||
糧積壓齋願醖膚餘淵蓋(壓積範壓壓築構蓋憲醖) = 觸憲鹽窪糧鹹簾構膚積 遞壓鏇艱齋廠鹽淵糧積 (鑰製糧網醖鏇壓願糧鹽 ) | |||||||
N/A | - | 醖築鏇艱膚選鏇鏇淵獵(顧齋憲襯構願醖衊淵範) = 獵襯壓遞簾願齋廠築築 醖簾積襯蓋遞夢鏇廠壓 (蓋襯淵夢觸簾蓋艱艱糧 ) | 积极 | 2017-05-07 | |||
Topical saline | 醖築鏇艱膚選鏇鏇淵獵(顧齋憲襯構願醖衊淵範) = 遞遞夢夢築餘憲構蓋蓋 醖簾積襯蓋遞夢鏇廠壓 (蓋襯淵夢觸簾蓋艱艱糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用